Methodist Journal

IN THIS ISSUE

Adult Congenital Heart Update

Vol 15, Issue 2 (2019)


FEATURED GUEST EDITOR

ISSUE INTRO

The Growing Number of Adults Surviving with Congenital Heart Disease

See More
RECOGNITIONS

Drs. MacGillivray and Lin Take the Lead in Adult Congenital Heart Disease

See More

REVIEW ARTICLES See More

Advanced Cardiac Imaging for Complex Adult Congenital Heart Diseases

149 Fontan Conversions

Anomalous Aortic Origin of a Coronary Artery

Pulmonary Valve Replacement for Tetralogy of Fallot

Management of the Adult with Arterial Switch

Ebstein’s Anomaly

Heart Transplantation in Adults with Congenital Heart Disease

Cholesterol: Can’t Live With It, Can’t Live Without It

CASE REPORTS See More

Simultaneous Transfemoral Mitral and Tricuspid Valve in Ring Implantation: First Case Report with Edwards Sapien 3 Valve

Uneventful Follow-Up 2 Years after Endovascular Treatment of a High Flow Iatrogenic Aortocaval Fistula Causing Pulmonary Hypertension and Right Heart Failure

Device-Related Thrombus: A Reason for Concern?

Retained Coronary Balloon Requiring Emergent Open Surgical Retrieval: An Uncommon Complication Requiring Individualized Management Strategies

MUSEUM OF HMH MULTIMODALITY IMAGING CENTER See More

Do I Look Fat in This? Multimodality Imaging Findings of a Cardiac Lipoma

CLINICAL PERSPECTIVES See More

POINTS TO REMEMBER

The Kidney in Congenital Cyanotic Heart Disease

EXCERPTA

Talking Statins with Antonio Gotto

POINTS TO REMEMBER

Lipids and Renal Disease

EXCERPTA

Addressing the Feedback Loop Between Depression, Diabetes, and Cardiovascular Disease

EDITORIALS

Letter to the Editor in Response to “Cardiac Autonomic Neuropathy in Diabetes Mellitus”

Vol 15, Issue 1 (2019)

Article Full Text

REVIEW ARTICLES

Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability

Jump to:
Article Citation:

Rosales C, Gillard BK, Xu B, Gotto AM Jr, Pownall HJ. Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability. Methodist DeBakey Cardiovasc J. 2019:15(1):47-54.



Abstract

Dysregulated free cholesterol (FC) metabolism has been implicated in nearly all stages of atherosclerosis, the underlying cause of most cardiovascular disease. According to a widely cited model, the burden of macrophage FC in the arterial wall is relieved by transhepatic reverse cholesterol transport (RCT), which comprises three successive steps: (1) macrophage FC efflux to high-density lipoprotein (HDL) and/or its major protein, apolipoprotein AI; (2) FC esterification by lecithin:cholesterol acyltransferase (LCAT); and (3) HDL-cholesteryl ester (CE) uptake via the hepatic HDL-receptor, scavenger receptor class B type 1 (SR-B1). Recent studies have challenged the validity of this model, most notably the role of LCAT, which appears to be of minor importance. In mice, most macrophage-derived FC is rapidly cleared from plasma (t1/2 < 5 min) without esterification by hepatic uptake; the remainder is taken up by multiple tissue and cell types, especially erythrocytes. Further, some FC is cleared by the nonhepatic transintestinal pathway. Lastly, FC movement among lipid surfaces is reversible, so that a higher-than-normal level of HDL-FC bioavailability—defined by high plasma HDL levels concurrent with a high mol% HDL-FC—leads to the transfer of excess FC to cells in vivo. SR-B1-/- mice provide an animal model to study the mechanistic consequences of high HDL-FC bioavailability that provokes atherosclerosis and other metabolic abnormalities. Future efforts should aim to reduce HDL-FC bioavailability, thereby reducing FC accretion by tissues and the attendant atherosclerosis.

Keywords
free cholesterol bioavailability , reverse cholesterol transport , cholesterol , high density lipoproteins , atherogenesis , lipid metabolism

CHOLESTEROL AND ATHEROGENESIS 

Figure 1. (A) Hazard ratio by high-density lipoprotein cholesterol (HDL-C) quintile. (B) Correlation of HDL percentile with HDL-C level; red bar denotes the range for the “optimal” HDL-C level from A. MetS: metabolic syndrome; DysHDL: dysfunctional HDL

Beginning with the studies of Nikolay Anichkov, excess cholesterol has been intimately associated with the pathophysiology of atherosclerotic cardiovascular disease (ASCVD).1,2 Atherosclerosis begins with cholesterol accumulation within macrophages in the subendothelial space of the arterial wall. As the cholesterol burden grows, cholesterol-rich lesions form on the arterial wall. High plasma levels of low-density lipoprotein cholesterol (LDL-C) is a positive risk factor for ASCVD. Statins reduce that risk by inhibiting cholesterol biosynthesis, thereby increasing the number of hepatic LDL receptors that mediate plasma LDL-C disposal. Even with the success of statins, residual ASCVD still occurs, albeit at a lower rate, due to other lipid risk factors, especially low plasma levels of high-density lipoprotein cholesterol (HDL-C). Studies by Gofman and others, including the Framingham Heart Study, showed an association between low plasma HDL-C concentrations and increased ASCVD.3-5 This observation provoked the Helsinki Heart Study, in which gemfibrozil increased plasma HDL-C concentrations and reduced ASCVD,6 a finding confirmed by the Veterans Affairs HDL Intervention Trial.7

Despite these early reports, a growing body of evidence has challenged the hypothesis that increasing plasma HDL-C is cardioprotective and questioned the direct mechanistic link between HDL-C and cardioprotection based on the following:

  1. Genetically elevated plasma apolipoprotein AI (apoAI) and HDL-C levels do not reduce ASCVD risk.8
  2. An HDL-C–raising endothelial lipase variant is not associated with reduced ASCVD.9
  3. Many patients with low HDL-C levels do not develop ASCVD, and vice versa.
  4. In the AIM-HIGH trial, niacin added to a statin increased HDL-C but did not reduce ASCVD.10
  5. Patients with cholesteryl ester transfer protein (CETP) deficiency, which profoundly increases plasma HDL-C levels, do not experience a commensurate ASCVD reduction predicted by observational data.11
  6. CETP inhibitors, which increase plasma HDL-C levels, fail to reduce ASCVD events.12-14

Other studies reveal a more complex, nonlinear relationship between plasma HDL-C levels and ASCVD mortality, with the extremes of high and low HDL-C concentrations being associated with more all-cause and, in some reports, cardiovascular disease mortality.15-18 This association, recently reinvestigated using a pooled analysis of a large population (n = 37,059),19 revealed a U-shaped curve, wherein the highest hazard ratio is at the extremes of the plasma HDL-concentrations (Figure 1 A). The middle quintile, the “sweet spot,” covers a plasma HDL-C range from 58 to < 77 mg/dL. The distribution of mean plasma HDL-C concentrations for 40- to 44-year-old males and females according to percentile is shown in Figure 1 B.20 Superimposing the middle quintile in Figure 1 A onto the bottom plot (Figure 1 B) shows that most male subjects with a high hazard ratio have low plasma HDL-C concentrations, while approximately 10% of female subjects have a high hazard ratio due to high HDL-C concentration; the middle quintile denoted by the red bar is the hazard-ratio optimum. The underlying cause of the high hazard ratio at low HDL-C concentrations has been linked to factors that cluster with low plasma HDL-C levelssmokers, physical inactivity, elevated body mass index, high systolic blood pressure—collectively simulating the metabolic syndrome (MetS) phenotype.19 The underlying cause for the increased hazard ratio in the highest quintile of HDL-C levels are not known. In the world of precision medicine, patients at higher ASCVD risk due to high or low plasma HDL-C levels should be treated differently. However, the treatment plan would depend upon underlying causes, which for high plasma HDL-C levels are not known.

TRANSHEPATIC REVERSE CHOLESTEROL TRANSPORT

Figure 2. Traditional reverse cholesterol transport model comprises three steps: (1) macrophage free cholesterol efflux to apolipoprotein AI via the ATP-binding cassette transporter A1 (ABCA1) yields nascent high-density lipoprotein (nHDL); (2) nHDL esterification by lecithin:cholesterol acyltransferase (LCAT) gives spherical HDL; and (3) selective hepatic uptake of HDL cholesterol ester.

HDL is thought to elicit a cardioprotective effect through its role in reverse cholesterol transport (RCT), the transfer of cholesterol from macrophages in the arterial wall to the liver for intestinal disposal (Figure 2). The initial RCT step—cholesterol efflux from macrophages to apoAI via the ATP-binding cassette transporter member 1 (ABCA1)—forms nascent (n)HDL. This is followed by esterification of HDL free cholesterol (HDL-FC) by lecithin:cholesterol acyltransferase (LCAT), which forms mature, spherical HDL with a cholesteryl ester (CE) core. Finally, HDL lipids, including FC and CE, are selectively removed by the hepatic HDL receptor, scavenger receptor class B type 1 (SR-B1), leaving a remnant of mostly phospholipid and protein and lipid-free apoAI.21,22

Given the evidence against the raising-HDL-is-better hypothesis, research focus shifted from HDL quantity to HDL qualities that better support RCT. One of these is the capacity of plasma to accept FC from macrophages, which begs the question, “Do patients with ASCVD have impaired FC efflux compared to healthy, ASCVD-free individuals?” Two large studies addressed this question and found that the magnitude of macrophage cholesterol efflux to HDL negatively correlates with ASCVD, a correlation that persists even after adjustment for plasma HDL-C and apoAI concentrations.23,24 Thus, FC efflux is a metric of HDL function that inversely associates with ASCVD. This metric is not predictively axiomatic due to confounders that have yet to be identified.

REVERSIBILITY OF CHOLESTEROL EFFLUX

Free cholesterol is sparingly soluble in water, ~30 nM.25 For this reason, FC can transfer between membrane and lipoprotein surfaces by rate-limiting desorption from a lipid surface into the surrounding aqueous phase. This step is followed by rapid, diffusion-controlled transfer to another lipid surface or return to the same surface. Transfer of FC between lipid surfaces occurs on a measurable time scale; FC transfer from HDL and LDL occurs with t1/2 = 5 and 45 min, respectively.26 Thus, if the macrophage FC burden is relieved by efflux to HDL, it can also be increased by influx from HDL, the rate of which would depend on qualities of HDL that control the rate of HDL-FC desorption.

CELLULAR STUDIES OF REVERSIBLE CHOLESTEROL FLUX

Figure 3. Cell free cholesterol (FC), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), and acyl-coenzyme A:cholesterol acyltransferase (ACAT) as a function of reassembled high-density lipoprotein (rHDL) mol% FC as labeled.

According to the traditional Glomset/Ross RCT hypothesis as it has evolved, FC efflux to HDL relieves the FC burden of arterial-wall macrophages, thereby preventing or reversing atherogenesis. However, FC moves freely and reversibly between and across lipid surfaces of cell membranes and plasma lipoproteins,27 so that dysfunctional HDL that supports FC influx into cells could be atherogenic. The balance of FC efflux versus influx between macrophages and reassembled HDL (rHDL) has been studied as a function of the rHDL-FC content, expressed as mol% FC.28 Decreased and increased cell-associated FC corresponds to efflux and influx, respectively. In the study by Picardo et al., cellular FC efflux to rHDL containing no FC (0 mol%) increased with increasing rHDL concentration. As the rHDL-FC content increased to 50 mol%, FC flux shifted from efflux to influx. Moreover, the magnitude of the efflux and influx increased with rHDL concentrations, reaching a maximum effect at 50 µg/mL HDL-protein. Cellular FC biosynthesis according to HMG-CoA reductase (HMGR) activity decreased with increasing cellular FC content. Thus, during efflux and influx, which decrease and increase cell FC content, respectively, HMGR activity increases and decreases. At high cellular FC content, the FC is detoxified by its conversion to CE via acyl-CoA-cholesterol acyltransferase (ACAT); consequently, as cellular FC content increases, so does CE formation. The effects of rHDL on cell FC, HMGR, and ACAT were most profound at high rHDL concentrations. A plot of cell FC, HMGR, and ACAT activities versus the rHDL mol% FC at 50 µg/mL rHDL-protein reveals that between 5 and 20 mol% rHDL-FC, rHDL switches from FC acceptor to FC donor (Figure 3). Extrapolation of these data to human physiology suggests that high plasma concentrations of HDL with high FC content would support net FC transfer to tissues, an atherogenic process.

A MOUSE MODEL OF DYSFUNCTIONAL HDL DUE TO HIGH HDL-FC BIOAVAILABILITY

Mice deficient in the HDL receptor SR-B1 are robust models of dysfunctional high plasma HDL-C levels. Compared to wild type (WT) mice, HDL in SR-B1-/- mice is larger and richer in FC (~15 vs ~60 mol%, respectively); plasma HDL levels of SR-B1-/- mice are two-times higher than those of WT.29 SR-B1-/- mice are characterized by multiple metabolic defects, such as abnormal platelet and erythrocyte structure and function and infertility among female mice.30 Moreover, when put on a high-fat, high-cholesterol diet, the mice develop atherosclerosis despite a doubling of the HDL concentration and without a meaningful change in the plasma concentration of apoB-containing lipoproteins.31 Thus, while it is by far the most abundant plasma lipoprotein among SR-B1-/- mice, some property of HDL is toxic. We reiterate our hypothesis that the pathological quality of SR-B1-/- HDL is a high HDL-FC bioavailability that is supported by a high plasma HDL concentration (i.e., a high particle number, and a high mol% FC). Comparison of the aforementioned mol% values with the data of Figure 3 suggests that the HDL of SR-B1-/- mice would strongly support FC influx into cells. Notably, the lipid-lowering drug probucol restores some function, including fertility.30,32 However, this is a partial effect in that probucol reduces the atherogenicity of HDL by reducing its plasma concentration without profoundly affecting HDL-FC content.

Figure 4. Comparison of free cholesterol (FC) transfer from wild type (WT) and scavenger receptor class B type 1 (SR-B1)-/- high-density lipoprotein (HDL) mice. The initially higher mol% FC in SR-B1-/- versus WT HDL results in more transfer to LDL at equilibrium (t = 20 min).

The importance of mol% HDL-FC is illustrated in the kinetic model in Figure 4, which compares the transfer mechanism and final transfer of FC between WT versus SR-B1-/- mice. This model shows that the greater amount of FC transfer from SR-B1-/- HDL is due to its higher mol% FC. Given that the rate-limiting step for HDL-FC transfer to all tissue and lipoprotein sites is the initial desorption, HDL-FC transfer to LDL is a valid metric for transfer to all tissues and lipoproteins.

Genetic studies of human SCARB1 (the SR-B1 gene) variants positively associate with plasma HDL-C levels and peripheral cellular SR-B1-protein levels.33 Carriers of an SR-B1 variant have increased HDL-C levels, impaired cholesterol efflux, altered platelet function, and reduced adrenal steroidogenesis.34 In the context of the HDL–SR-B1–atherogenesis axis, patients heterozygous for the SR-B1 variant (P376L, where leucine replaces proline 376) showed increased plasma HDL-C levels and ASCVD35; in addition, the rs10846744 single nucleotide polymorphism in the SCARB1 enhancer region is also associated with ASCVD.36 Although loss of SR-B1 function appears to be pathological, the HDL–SR-B1–atherogenesis axis is complex; ultra-high SR-B1 expression, which induces low HDL levels, is nearly as atherogenic as SR-B1 deficiency.37 Currently, there are no approved cardioprotective therapies for elevated and/or dysfunctional HDL with underlying HDL-FC hyper-bioavailability.

IN VIVO NHDL KINETICS

Although the traditional Glomset/Ross RCT model (Figure 2) has been implicated in many studies of FC transport—including those showing that the magnitude of FC efflux (the first step) inversely correlates with ASCVD incidence—it was never rigorously tested until recently. FC efflux to apoAI produces nascent (n)HDL, which contains FC, apoAI, and cell-derived phospholipids (PL). Xu et al. tested a triply labeled nHDL via the interaction of [125I]apoAI with BHK cells overexpressing the ABCA1 transporter and labeled with [3H]FC and [14C]PL.38 The labeled nHDL was injected into mice, and the rates of clearance and tissue sites of label accumulation were determined. As proposed in the traditional RCT model, most FC and PL were cleared by the liver. However, the data were inconsistent with the traditional RCT model, which implicates LCAT in RCT. The clearance of the main LCAT substrates, FC and PL, was rapid, t1/2 = ~5 and 2 min, respectively—times during which only ~2% of FC was esterified. Thus, LCAT plays a minor role in most RCT. Given the rapid clearance of FC and the minor role of LCAT, one would also conclude that selective CE uptake via SR-B1 plays a minor role in RCT. However, in light of other data, SR-B1 likely mediates a major fraction of hepatic FC clearance; overexpression of SR-B1 in mice accelerates hepatic FC uptake.39 SR-B1 also transfers a greater fraction of HDL-FC versus CE into cells.40 Thus, a major fraction of nHDL is cleared via SR-B1, although spontaneous SR-B1–independent uptake is also likely important because it, too, occurs in minutes.26 Similar studies in humans showed a t1/2 < 10 min for plasma clearance of HDL-FC.41 Thus, these data support the hypothesis that most RCT is simply reverse free cholesterol transport and involves little LCAT-derived CE. Collectively, these data support a revised model of RCT (Figure 5).38

TRANSINTESTINAL CHOLESTEROL EXCRETION AND FC BIOAVAILABILITY

Figure 5. A revised reverse cholesterol transfer (RCT) model. In this model, (1) free cholesterol (FC) efflux to apolipoprotein AI (apoAI) via the ATP-binding cassette transporter A1 (ABCA1) forms nascent high-density lipoprotein (nHDL), which (2) transfers some of its FC to HDL within the plasma compartment (defined by the rectangle). (3, 4) FC transfers to the liver via scavenger receptor class B type 1 (SR-B1) and spontaneous transfer (5) and to erythrocytes. Concurrently, (6) some apoAI is released from nHDL and HDL for another cycle of efflux. PL: phospholipid

Studies show that there is some FC transfer to the feces independent of bile.42,43 For example, Pertsemlidis and colleagues found FC in the feces of dogs whose bile was diverted to the urinary system.44 In another study by Yu, mice with deleted hepatic FC transporter had high fecal neutral sterol levels, but their biliary cholesterol secretion rates were almost nonexistent.45 These findings suggest that FC elimination may occur through direct transintestinal cholesterol excretion (TICE), which only involves FC, not CE.46 This can occur via two mechanisms, the first being spontaneous transfer from plasma lipoproteins to the intestine and other tissue sites. The transfer of FC to lipoprotein and membrane surfaces from HDL is rapid, t1/2 ~5 min,26 whereas FC transfer across membranes is < 1 sec.47-49 Consequently, TICE may start with spontaneous FC transfer from lipoproteins to membranes in contact with the plasma compartment followed by diffusion to numerous phospholipid-containing loci between plasma and the intestine. The other possible TICE mechanism involves cholesterol transporters on the plasma membrane of various cellular interfaces between the plasma compartment and the intestine. One of these transporters is SR-B1, which facilitates bidirectional FC transit.50  To have net transfer to excretion, this process must include an irreversible step that sequesters FC. Since intestinal PL content is a positive regulator of TICE, and PL is the cholesterophilic component of bile, a high concentration of intestinal bile-phospholipid would support net RCT via TICE.51,52 TICE may be stimulated by dietary changes that include and sustain a high bile-phospholipid content, thereby contributing to whole-body FC disposal.

The relative contributions of spontaneous and SR-B1–mediated transfer to TICE are unknown. However, TICE is probably only one component of FC transfer to multiple tissue sites. Although our data showed rapid hepatic FC uptake in mice over longer time intervals, the FC appeared in nearly every tissue site, especially erythrocytes (13% at max).38 Thus, FC is highly mobile and goes to any tissue or cell site by diffusion.53

IMPORTANCE OF PLASMA HDL-FC BIOAVAILABILITY IN VIVO

Comparison of the in vivo rates of FC24 and CE flux54,55 reveals that FC flux is an order of magnitude faster than that of CE and several orders of magnitude faster than lipoprotein turnover, which occurs in hours to days.56,57 Thus, one would expect FC flux among cells and lipoproteins to be an important determinant of its metabolic and pathophysiological effects. Although in vitro studies in cells show that a high mol% FC in HDL and high plasma HDL concentration promotes influx,28 complementary in vivo data are lacking. Moreover, most large clinical trials focus on total cholesterol and LDL-C, which contain the sum of FC and CE; there is little data on the relationship, if any, between plasma and/or HDL-FC and ASCVD and whether FC bioavailability contributes to ASCVD risk reduction achieved by statin therapy. Nevertheless, it is relevant and supportive of our hypothesis that the HDL:(TC/PL) ratio of patients with very high HDL-C was 20% higher and the plasma efflux capacity was lower than in those with normal HDL-C. Although they did not report HDL-FC influx to cells nor the HDL-(FC/PL) ratio, which would determine mol% FC, this report supports the hypothesis that FC bioavailability is higher among the high HDL-C patients.58

CONCLUSION

Free cholesterol transport among plasma lipoproteins and various tissues occurs by multiple mechanisms. One minor pathway is LCAT-mediated conversion to CE, which is hepatically extracted by SR-B1–mediated selective uptake. Another is spontaneous and SR-B1–mediated FC transfer to multiple tissue sites, especially the liver. Spontaneous transfer, such as diffusion, mediates the appearance of lipoprotein-derived FC in nearly all tissues and red blood cells. A high plasma HDL-FC is possibly atherogenic and toxic to some tissues. New approaches to reduce HDL-FC bioavailability are needed to control FC cytotoxicity that is associated with high plasma HDL and high HDL-FC per particle content.

KEY POINTS  

  • Recent studies support changes to the widely cited reverse cholesterol transport (RCT) mechanism. Foremost among these is the minimal involvement of lecithin:cholesterol acyltransferase (LCAT)-mediated free cholesterol (FC) esterification, which is interesting given that the discovery of LCAT provoked formulation of the traditional RCT mechanism.
  • Mechanistically, FC transfer to the liver occurs via spontaneous transfer and scavenger receptor class B type 1–mediated uptake.
  • The FC content of high-density lipoprotein (HDL) and the plasma HDL concentration are both determinants of FC bioavailability, which may be an important determinant of several pathological states, including atherosclerosis.
Conflict of Interest Disclosure

Dr. Gotto is a consultant for Esperion and KOWA Pharmaceuticals America, Inc. and is on the Data Safety Monitoring Board for Ionis Pharmaceuticals.

References
  1. Anichkov NN. A history of experimentation on arterial atherosclerosis in animals. In: Blumenthal HT, editor. Cowdry’s arteriosclerosis: a survey of the problem. 2nd ed. Springfield, IL: Charles C. Thomas Publishing; 1967. p. 21-46.
  2. Finking G, Hanke H. Nikolaj Nikolajewitsch Anitschkow (1885–1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis. 1997 Nov;135(1):1-7.
  3. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation. 1966 Oct;34(4):679-97.
  4. Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. 1977 May;55(5):767-72.
  5. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977 May;62(5):707-14.
  6. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237-45.
  7. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999 Aug 5;341(6):410-8.
  8. Haase CL, Tybjærg-Hansen A, Grande P, Frikke-Schmidt R. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab. 2010 Dec;95(12):E500-10.
  9. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012 Aug 11;380(9841):572-80.
  10. Boden WE, Probstfield JL, Anderson T, et al.; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 Dec 15;365(24):2255-67.
  11. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996 Jun 15;97(12):2917-23.
  12. Schwartz GG, Olsson AG, Abt M, et al.; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29;367(22):2089-99.
  13. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):257-60.
  14. Zhao HP, Xiang BR. Discontinued cardiovascular drugs in 2013 and 2014. Expert Opin Investig Drugs. 2015;24(8):1083-92.
  15. Ko DT, Alter DA, Guo H, et al. High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions: The CANHEART Study. J Am Coll Cardiol. 2016 Nov 8;68(19):2073-83.
  16. Bowe B, Xie Y, Xian H, Balasubramanian S, Zayed MA, Al-Aly Z. High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans. Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1784-93.
  17. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017 Aug 21;38(32):2478-86.
  18. Madsen CM, Nordestgaard BG. Is It Time for New Thinking About High-Density Lipoprotein? Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):484-6.
  19. Hamer M, O’Donovan G, Stamatakis E. High-Density Lipoprotein Cholesterol and Mortality: Too Much of a Good Thing? Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):669-72.
  20. Schaefer EJ. Clinical, biochemical, and genetic features in familial disorders of high density lipoprotein deficiency. Arteriosclerosis. 1984 Jul-Aug;4(4):303-22.
  21. Gillard BK, Bassett GR, Gotto AM Jr, Rosales C, Pownall HJ. Scavenger receptor B1 (SR-B1) profoundly excludes high density lipoprotein (HDL) apolipoprotein AII as it nibbles HDL-cholesteryl ester. J Biol Chem. 2017 May 26;292(21):8864-73.
  22. Glass C, Pittman RC, Weinstein DB, Steinberg D. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc Natl Acad Sci U S A. 1983 Sep;80(17):5435-9.
  23. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011 Jan 13;364(2):127-35.
  24. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014 Dec 18;371(25):2383-93.
  25. Haberland ME, Reynolds JA. Self-association of cholesterol in aqueous solution. Proc Natl Acad Sci U S A. 1973 Aug;70(8):2313-6.
  26. Lund-Katz S, Hammerschlag B, Phillips MC. Kinetics and mechanism of free cholesterol exchange between human serum high- and low-density lipoproteins. Biochemistry. 1982 Jun 8;21(12):2964-9.
  27. Phillips MC, Johnson WJ, Rothblat GH. Mechanisms and consequences of cellular cholesterol exchange and transfer. Biochim Biophys Acta. 1987 Jun 24;906(2):223-76.
  28. Picardo M, Massey JB, Kuhn DE, Gotto AM Jr, Gianturco SH, Pownall HJ. Partially reassembled high density lipoproteins. Effects on cholesterol flux, synthesis, and esterification in normal human skin fibroblasts. Arteriosclerosis. 1986 Jul-Aug;6(4):434-41.
  29. Ma K, Forte T, Otvos JD, Chan L. Differential additive effects of endothelial lipase and scavenger receptor-class B type I on high-density lipoprotein metabolism in knockout mouse models. Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):149-54.
  30. Miettinen HE, Rayburn H, Krieger M. Abnormal lipoprotein metabolism and reversible female infertility in HDL receptor (SR-BI)-deficient mice. J Clin Invest. 2001 Dec;108(11):1717-22.
  31. Van Eck M, Twisk J, Hoekstra M, et al. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. J Biol Chem. 2003 Jun 27;278(26):23699-705.
  32. Braun A, Zhang S, Miettinen HE, et al. Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7283-8.
  33. West M, Greason E, Kolmakova A, et al. Scavenger receptor class B type I protein as an independent predictor of high-density lipoprotein cholesterol levels in subjects with hyperalphalipoproteinemia. J Clin Endocrinol Metab. 2009 Apr;94(4):1451-7.
  34. Vergeer M, Korporaal SJ, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med. 2011 Jan 13;364(2):136-45.
  35. Zanoni P, Khetarpal SA, Larach DB, et al.; CHD Exome+ Consortium; CARDIoGRAM Exome Consortium; Global Lipids Genetics Consortium. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 2016 Mar 11;351(6278):1166-71.
  36. Golden D, Kolmakova A, Sura S, et al. Lymphocyte activation gene 3 and coronary artery disease. JCI Insight. 2016 Oct 20;1(17):e88628.
  37. Ueda Y, Gong E, Royer L, Cooper PN, Francone OL, Rubin EM. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J Biol Chem. 2000 Jul 7;275(27):20368-73.
  38. Xu B, Gillard BK, Gotto AM Jr, Rosales C, Pownall HJ. ABCA1-Derived Nascent High-Density Lipoprotein-Apolipoprotein AI and Lipids Metabolically Segregate. Arterioscler Thromb Vasc Biol. 2017 Dec;37(12):2260-70.
  39. Ji Y, Wang N, Ramakrishnan R, et al. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile. J Biol Chem. 1999 Nov 19;274(47):33398-402.
  40. Thuahnai ST, Lund-Katz S, Williams DL, Phillips MC. Scavenger receptor class B, type I-mediated uptake of various lipids into cells. Influence of the nature of the donor particle interaction with the receptor. J Biol Chem. 2001 Nov 23;276(47):43801-8.
  41. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res. 2004 Sep;45(9):1594-607.
  42. Miettinen TA, Proia A, McNamara DJ. Origins of fecal neutral steroids in rats. J Lipid Res. 1981 Mar;22(3):485-95.
  43. Chevallier F. [Study of the origin of fecal sterols in the rat by means of radioactive indicators. 1. Demonstration of the secretion of sterols into the intestinal contents]. Bull Soc Chim Biol (Paris). 1960;42:623-32.
  44. Pertsemlidis D, Kirchman EH, Ahrens EH Jr. Regulation of cholesterol metabolism in the dog. I. Effects of complete bile diversion and of cholesterol feeding on absorption, synthesis, accumulation, and excretion rates measured during life. J Clin Invest. 1973 Sep;52(9):2353-67.
  45. Yu L, Li-Hawkins J, Hammer RE, et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest. 2002 Sep;110(5):671-80.
  46. van der Velde AE, Vrins CL, van den Oever K, et al. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology. 2007 Sep;133(3):967-75.
  47. Lange Y, Dolde J, Steck TL. The rate of transmembrane movement of cholesterol in the human erythrocyte. J Biol Chem. 1981 Jun 10;256(11):5321-3.
  48. Hamilton JA. Fast flip-flop of cholesterol and fatty acids in membranes: implications for membrane transport proteins. Curr Opin Lipidol. 2003 Jun;14(3):263-71.
  49. Backer JM, Dawidowicz EA. The rapid transmembrane movement of cholesterol in small unilamellar vesicles. Biochim Biophys Acta. 1979 Mar 8;551(2):260-70.
  50. Yancey PG, de la Llera-Moya M, Swarnakar S, et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem. 2000 Nov 24;275(47):36596-604.
  51. Niu SL, Litman BJ. Determination of membrane cholesterol partition coefficient using a lipid vesicle-cyclodextrin binary system: effect of phospholipid acyl chain unsaturation and headgroup composition. Biophys J. 2002 Dec;83(6):3408-15.
  52. Tchoua U, Gillard BK, Pownall HJ. HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis. 2010 Apr;209(2):430-5.
  53. Gillard BK, Rosales C, Xu B, Gotto AM Jr, Pownall HJ. Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins. J Clin Lipidol. 2018 Jul – Aug;12(4):849-56.
  54. Barter PJ, Jones ME. Rate of exchange of esterified cholesterol between human plasma low and high density lipoproteins. Atherosclerosis. 1979 Sep;34(1):67-74.
  55. Nestel PJ, Monger EA. Turnover of plasma esterified cholesterol in normocholesterolemic and hypercholesterolemic subjects and its relation to body build. J Clin Invest. 1967 Jun;46(6):967-74.
  56. Blum CB, Levy RI, Eisenberg S, Hall M 3rd, Goebel RH, Berman M. High density lipoprotein metabolism in man. J Clin Invest. 1977 Oct;60(4):795-807.
  57. Langer T, Strober W, Levy RI. The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J Clin Invest. 1972 Jun;51(6):1528-36.
  58. Agarwala AP, Rodrigues A, Risman M, et al. High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1515-9.

Add Comments

Please login to dialogue with author.

Comments